Sanofi’s venglustat succeeds in Phase 3 Gaucher trial but fails separate study in Fabry diseasenews2026-02-02T12:12:25+00:00February 2nd, 2026|Endpoints News|
Pharming’s immunodeficiency drug gets CRL for use in younger patientsnews2026-02-02T11:52:52+00:00February 2nd, 2026|Endpoints News|
European law changes mean drugmakers may have to grapple with generic competition soonernews2026-02-02T06:00:46+00:00February 2nd, 2026|Endpoints News|
Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and morenews2026-01-31T11:00:35+00:00January 31st, 2026|Endpoints News|
FDA says it explained issues early on for Corcept’s rejected Cushing’s syndrome drugnews2026-01-30T19:14:25+00:00January 30th, 2026|Endpoints News|
Bitterroot reverts to preclinical biotech in CD47 as CEO leavesnews2026-01-30T17:30:44+00:00January 30th, 2026|Endpoints News|
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshildnews2026-01-30T17:18:18+00:00January 30th, 2026|Endpoints News|
Ultragenyx resubmits gene therapy for rare neuro disease to FDAnews2026-01-30T16:50:40+00:00January 30th, 2026|Endpoints News|
Quince’s steroid therapy for rare disease fails, shares tanknews2026-01-30T16:17:55+00:00January 30th, 2026|Endpoints News|
Moderna licenses Phase 3 asset to Recordati; ProMIS’ private placementnews2026-01-30T16:05:18+00:00January 30th, 2026|Endpoints News|
